In the global pharmaceutical landscape, hereditary angioedema (HAE) remains a significant area of focus, given its rarity and the impact it has on patients. Trials are typically conducted in a rigorous manner given that this relates to deficiency of critical enzyme called C1 Esterase Inhibitor (C1-INH). The volume of these...
Discover more insightsHereditary Angioedema (HAE) is a rare, but potentially fatal genetic disorder characterized by sudden, repeated attacks of severe swelling. The current therapeutic landscape for HAE is marked by a burgeoning innovation, largely driven by a greater understanding of disease pathophysiology and advanced gene therapies. There is a growing arsenal of...
Discover more insights